Another venture capital firm that backs biotechs has raised a multimillion-dollar fund—money the firm, Cambridge, MA-based Atlas Venture, says it will use to continue creating and funding companies that are working to create new medicines.

Atlas revealed Friday that it closed its 12th fund after raising $400 million, a total that pushes the amount the company has raised in the past few years to $1 billion. In addition to Fund XXII and its previous fund, for which it raised $350 million in 2017, Atlas last year put together what it calls Opportunity Fund I, a $250 million pot of money Read more »